Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 18 - 150 Days
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required